Canadian researchers have found what they hope is a magic bullet in combating diabetes.
McMasters University scientists are crediting extra use by the commonly prescribed Rosiglitazone for the hope of cutting the diabetes epidemic in half, the Hamilton Spectator said.
Widely used to treat type 2 diabetes, Rosiglitazone has been found effective for those at highest risk because of genetics, age or obesity, making it what researchers call the first line of defense for diabetes.
The results of the $25 million study were presented Friday at the annual meeting of the European Association for the Study of Diabetes in Copenhagen.
Copyright 2006 by United Press International
Explore further: Researchers perform large genome-wide analysis of multiple sclerosis